Integrating genetic and lung tissue proteomics data to identify susceptibility proteins for lung cancer

Background Proteins directly impact disease development and act as drug targets. We integrated genetic and lung tissue proteomic data to identify lung cancer susceptibility proteins and evaluated them as candidate drug targets. Method We profiled the proteome and genome in 200 non-neoplastic lung tissue samples and constructed genetic models to predict protein abundance. These models were applied to genome-wide association study (GWAS) data of 55,174 lung cancer cases and 1,294,174 controls to evaluate associations between predicted abundance and lung cancer risk overall and by major histological subtypes. Independent lung tissue proteomic data was used for cross-dataset evaluation, followed by colocalization and summary-data-based Mendelian randomization. Prioritized proteins were cross-referenced against drug databases. Results We identified 29 lung cancer risk-associated proteins at a false discovery rate < 5%, including 25 for overall lung cancer, two (AQP3 and IL18) specific to adenocarcinoma, and two (HMGN2 and HLA-DMB) specific to squamous cell carcinoma. Genes encoding 15 proteins are located > 2Mb away from known GWAS risk loci. Among the remaining 14 proteins at known risk loci, five (EPHX2, CLDN18, PSMD5, ARHGAP27, and CYP2S1) showed associations independent of proximal lead variant. Of the 29 proteins, eight were predicted and six were significant in independent data. DSP, IL18 and TYMP proteins demonstrated both reproducible and potential causal evidence and are targeted by six drugs that are FDA-approved or in phase III trials. Conclusion Our study identified novel lung cancer susceptibility proteins and potential therapeutic targets, offering insights into lung cancer biology and informing future translational research.

Authors

Institutions

Publication Details

Journal
JNCI Journal of the National Cancer Institute
Published
2026-11-19
DOI
https://doi.org/10.1093/jnci/djag424
Citations
1
Primary Topic
Genetic Associations and Epidemiology
Type
article
Field-Weighted Citation Impact
1.71

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrating genetic and lung tissue proteomics data to identify susceptibility proteins for lung cancer

Xiao‐Ou Shu, Qiuyin Cai, Yaohua Yang, Bingshan Li et al.
1 citations
JNCI Journal of the National Cancer Institute
Genetic Associations and Epidemiology
1.71
article

Integrating genetic and lung tissue proteomics data to identify susceptibility proteins for lung cancer

Xiao‐Ou Shu, Qiuyin Cai, Yaohua Yang, Bingshan Li, Bing Zhang, Stephen A. Deppen, Yongchao Dou, Wanqing Wen, Xingyi Guo, Jirong Long, Jiajun Shi, Jie Wu, Ran TAO, Wei Zheng, Shuai Xu
article en
1 citations

Abstract

Background Proteins directly impact disease development and act as drug targets. We integrated genetic and lung tissue proteomic data to identify lung cancer susceptibility proteins and evaluated them as candidate drug targets. Method We profiled the proteome and genome in 200 non-neoplastic lung tissue samples and constructed genetic models to predict protein abundance. These models were applied to genome-wide association study (GWAS) data of 55,174 lung cancer cases and 1,294,174 controls to evaluate associations between predicted abundance and lung cancer risk overall and by major histological subtypes. Independent lung tissue proteomic data was used for cross-dataset evaluation, followed by colocalization and summary-data-based Mendelian randomization. Prioritized proteins were cross-referenced against drug databases. Results We identified 29 lung cancer risk-associated proteins at a false discovery rate < 5%, including 25 for overall lung cancer, two (AQP3 and IL18) specific to adenocarcinoma, and two (HMGN2 and HLA-DMB) specific to squamous cell carcinoma. Genes encoding 15 proteins are located > 2Mb away from known GWAS risk loci. Among the remaining 14 proteins at known risk loci, five (EPHX2, CLDN18, PSMD5, ARHGAP27, and CYP2S1) showed associations independent of proximal lead variant. Of the 29 proteins, eight were predicted and six were significant in independent data. DSP, IL18 and TYMP proteins demonstrated both reproducible and potential causal evidence and are targeted by six drugs that are FDA-approved or in phase III trials. Conclusion Our study identified novel lung cancer susceptibility proteins and potential therapeutic targets, offering insights into lung cancer biology and informing future translational research.

JNCI Journal of the National Cancer Institute
Baylor College of Medicine (US), Vanderbilt University (US), Vanderbilt-Ingram Cancer Center (US), University of Virginia (US)
Vanderbilt University, Vanderbilt-Ingram Cancer Center, National Institutes of Health, National Cancer Institute
Good health and well-being
Openalex Percentile: Top 25%
Genetic Associations and Epidemiology
1.71
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon